S.Amdt.2111 to S.3187112th Congress (2011-2012)
AmendmentHide Overview icon-hide
|Amends Bill:||S.3187 — Food and Drug Administration Safety and Innovation Act|
|Sponsor:||Sen. Bingaman, Jeff [D-NM] (Submitted 05/17/2012, Proposed 05/24/2012)|
|Latest Action:||05/24/2012 Amendment SA 2111, under the order of 5/23/12, not having achieved 60 votes in the affirmative, was not agreed to in Senate by Yea-Nay Vote. 28 - 67. Record Vote Number: 105.|
Purpose: S.Amdt. 2111 — 112th Congress (2011-2012)All Information (Except Text)
To provide substantial savings in health care costs to the Federal government and consumers by fostering competition among generic pharmaceutical manufacturers and ensuring that anti-competitive "pay-for-delay" settlements between brand-name and generic pharmaceutical manufacturers do not block generic drugs from entering the market.